2026 Collaborative Research Training Awards is still open!
Successful translational research relies on the seamless exchange of specialized techniques and expertise. To support this, the Collaborative Research Training Awards fund up to $2,000 research stays for trainees working on neuromuscular disease at Canadian institutions and applications are open to all trainees currently working in the NMD field in Canada. This includes MSc and PhD students, postdoctoral fellows as well as other research trainees.
Objectives of the Award
The program is structured to help trainees bridge technical gaps between laboratories. By facilitating a research stay at a different institution, the award allows participants to:
- Gain hands-on experience with specific experimental models or analytical techniques.
- Foster the transfer of knowledge that can be implemented in the trainee’s home laboratory.
- Build professional relationships that lead to more robust, multi-center research efforts.
Trainee Perspectives
The value of these collaborative exchanges is highlighted in our Early Career Blog series. Past recipients have shared how these research stays provided the specific technical edge and fresh perspectives required to progress their work.
For instance, Dr. Emilie Groulx-Boivin discusses the professional impact of expanding one’s scientific environment, while Dr. Jeremy Slayter highlights how technical exchange is essential for progressing early-career research. Their stories illustrate how stepping outside of one’s primary laboratory can catalyze new ideas and accelerate career development.
Application details and forms are available on the competition website, apply before June 15th 2026!
Visit Competition Webpage
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.